Literature DB >> 12475838

Costs of COPD in Sweden according to disease severity.

Sven-Arne Jansson1, Fredrik Andersson, Sixten Borg, Asa Ericsson, Elsy Jönsson, Bo Lundbäck.   

Abstract

OBJECTIVES: COPD is a common and disabling disease that entails high costs for society. The objectives of this study were to measure the societal costs of COPD in Sweden, and to examine the relationship between severity of illness and costs.
METHODS: The costs of COPD were examined using a well-defined and representative cohort of subjects with mild, moderate, and severe COPD. Regular telephone interviews regarding resource utilization were made to a cohort of 212 subjects with COPD derived from studies of the general population in Northern Sweden.
RESULTS: The annual per capita cost for COPD in Swedish crowns (SEK) was estimated at SEK 13,418 (1,284 US dollars (USD); 1,448 euros (EUR). The direct and indirect costs were SEK 5,592 (42%) and SEK 7,828 (58%), respectively. A highly significant relationship was found between severity of disease and costs. Costs for severe disease were 3 times as high as costs for moderate disease and > 10 times as high as for mild disease. Large individual variations in the level of costs were found.
CONCLUSION: Assuming that the prevalence and treatment patterns are representative of Sweden as a whole, the total costs of COPD to society in 1999 were estimated at SEK 9.1 billion (USD 871 million; EUR 982 million). Subjects with mild disease (83%) accounted for 29%, while subjects with moderate disease (13%) accounted for 41% of the total costs. The subjects with severe disease (4%) accounted for the remainder (30%). Prevention, early diagnosis, and postponement of disease progression should have large monetary and policy implications.

Entities:  

Mesh:

Year:  2002        PMID: 12475838     DOI: 10.1378/chest.122.6.1994

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  33 in total

Review 1.  Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004.

Authors:  M Decramer; R Gosselink; M Rutten-Van Mölken; J Buffels; O Van Schayck; P-A Gevenois; R Pellegrino; E Derom; W De Backer
Journal:  Thorax       Date:  2005-04       Impact factor: 9.139

2.  Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone.

Authors:  Claes-Göran Löfdahl; Asa Ericsson; Klas Svensson; Emma Andreasson
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  Insights about the economic impact of chronic obstructive pulmonary disease readmissions post implementation of the hospital readmission reduction program.

Authors:  Valerie G Press; R Tamara Konetzka; Steven R White
Journal:  Curr Opin Pulm Med       Date:  2018-03       Impact factor: 3.155

4.  The relationship between medical expenses and the severity of peripheral arterial disease in Japan.

Authors:  Akihiko Seo; Kota Yamamoto; Atsushi Akai; Daisuke Akagi; Toshio Takayama; Katsuyuki Hoshina
Journal:  Heart Vessels       Date:  2018-02-02       Impact factor: 2.037

5.  The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada.

Authors:  M Reza Maleki-Yazdi; Suzanne M Kelly; S Ys Lam; Mihaela Marin; Martin Barbeau; Valery Walker
Journal:  Can Respir J       Date:  2012 Sep-Oct       Impact factor: 2.409

6.  Present and future costs of COPD in Iceland and Norway: results from the BOLD study.

Authors:  R Nielsen; A Johannessen; B Benediktsdottir; T Gislason; A S Buist; A Gulsvik; S D Sullivan; T A Lee
Journal:  Eur Respir J       Date:  2009-04-08       Impact factor: 16.671

Review 7.  The global impact of non-communicable diseases on healthcare spending and national income: a systematic review.

Authors:  Taulant Muka; David Imo; Loes Jaspers; Veronica Colpani; Layal Chaker; Sven J van der Lee; Shanthi Mendis; Rajiv Chowdhury; Wichor M Bramer; Abby Falla; Raha Pazoki; Oscar H Franco
Journal:  Eur J Epidemiol       Date:  2015-01-18       Impact factor: 8.082

8.  Predicting Hospitalization Due to COPD Exacerbations in Swedish Primary Care Patients Using Machine Learning - Based on the ARCTIC Study.

Authors:  Björn Ställberg; Karin Lisspers; Kjell Larsson; Christer Janson; Mario Müller; Mateusz Łuczko; Bine Kjøller Bjerregaard; Gerald Bacher; Björn Holzhauer; Pankaj Goyal; Gunnar Johansson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-03-16

9.  The feasibility and validity of a remote pulse oximetry system for pulmonary rehabilitation: a pilot study.

Authors:  Jonathan Tang; Allison Mandrusiak; Trevor Russell
Journal:  Int J Telemed Appl       Date:  2012-09-24

Review 10.  New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses.

Authors:  Douglas W Mapel; Melissa H Roberts
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.